Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482209 | 0.91 | LPAR2 (0.42) | CCR2P2RX3LPAR2PTGS2TBXA2R | |
| SCHEMBL1482885 | 0.90 | KDM4E (0.42) | CCR2LPAR2TBXA2RTP53KDM4E | |
| SCHEMBL1482801 | 0.89 | TBXA2R (0.44) | CCR2P2RX3TBXA2RDCTPP1KDM4E | |
| SCHEMBL1482559 | 0.89 | TSHR (0.40) | CCR2LPAR2KDM4E | |
| SCHEMBL1482749 | 0.89 | P2RX3 (0.43) | P2RX3CNR1 | |
| SCHEMBL1482665 | 0.88 | KDM4E (0.47) | CCR2P2RX3TBXA2RKDM4EDRD2 | |
| SCHEMBL1482646 | 0.85 | DRD2 (0.53) | P2RX3TBXA2RDCTPP1TP53DRD2 | |
| SCHEMBL1482685 | 0.82 | KMT2A (0.48) | TP53KDM4EPTGESLMNA | |
| SCHEMBL1483074 | 0.82 | NR1H4 (0.49) | P2RX3LPAR2CNR1 | |
| SCHEMBL1484222 | 0.82 | DRD2 (0.38) | TBXA2RDCTPP1TP53DRD2GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | CCR2 2930/4885P2RX3 557/4885LPAR2 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.